Literature DB >> 18434369

Central and peripheral cardiovascular actions of adrenomedullin 5, a novel member of the calcitonin gene-related peptide family, in mammals.

Y Takei1, H Hashimoto, K Inoue, T Osaki, K Yoshizawa-Kumagaye, M Tsunemi, T X Watanabe, M Ogoshi, N Minamino, Y Ueta.   

Abstract

Adrenomedullin 5 (AM5) is a new member of the calcitonin gene-related peptide (CGRP) family identified in teleost fish. Although its presence was suggested in the genome database of mammals, molecular identity and biological function of AM5 have not been examined yet. In this study, we cloned a cDNA encoding AM5 in the pig and examined its cardiovascular and renal effects. Putative mature AM5 was localized in the middle of prohormone and had potential signals for intermolecular ring formation and C-terminal amidation. The AM5 gene was expressed most abundantly in the spleen and thymus. Several AM5 genes were newly identified in the database of mammals, which revealed that the AM5 gene exists in primates, carnivores, and undulates but could not be identified in rodents. In primates, nucleotide deletion occurred in the mature AM5 sequence in anthropoids (human and chimp) during transition from the rhesus monkey. Synthetic mature AM5 injected intravenously into rats induced dose-dependent decreases in arterial pressure at 0.1-1 nmol/kg without apparent changes in heart rate. The decrease was maximal in 1 min and AM5 was approximately half as potent as AM. AM5 did not cause significant changes in urine flow and urine Na+ concentration at any dose. In contrast to the peripheral vasodepressor action, AM5 injected into the cerebral ventricle dose-dependently increased arterial pressure and heart rate at 0.1-1 nmol. The increase reached maximum more quickly after AM5 (5 min) than AM (15-20 min). AM5 added to the culture cells expressing calcitonin receptor-like receptor (CLR) or calcitonin receptor (CTR) together with one of the receptor activity-modifying proteins (RAMPs), the combination of which forms major receptors for the CGRP family, did not induce appreciable increases in cAMP production in any combination, although AM increased it at 10(-)(10)-10(-)(9) M when added to the CLR and RAMP2/3 combination. These data indicate that AM5 seems to act on as yet unknown receptor(s) for AM5, other than CLR/CTR+RAMP, to exert central and peripheral cardiovascular actions in mammals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18434369     DOI: 10.1677/JOE-07-0541

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  5 in total

Review 1.  Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases.

Authors:  Song-Yang Zhang; Ming-Jiang Xu; Xian Wang
Journal:  Br J Pharmacol       Date:  2017-05-16       Impact factor: 8.739

Review 2.  Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.

Authors:  Debbie L Hay; Michael L Garelja; David R Poyner; Christopher S Walker
Journal:  Br J Pharmacol       Date:  2017-11-28       Impact factor: 8.739

Review 3.  The pharmacology of adrenomedullin 2/intermedin.

Authors:  Yanguo Hong; Debbie L Hay; Remi Quirion; David R Poyner
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

4.  Haemodynamic, endocrine and renal actions of adrenomedullin 5 in an ovine model of heart failure.

Authors:  Miriam T Rademaker; Christopher J Charles; M Gary Nicholls; A Mark Richards
Journal:  Clin Sci (Lond)       Date:  2012-05       Impact factor: 6.124

5.  Effect of environmental salinity on expression of adrenomedullin genes suggests osmoregulatory activity in the medaka, Oryzias latipes.

Authors:  Maho Ogoshi; Kanoko Kato; Tatsuya Sakamoto
Journal:  Zoological Lett       Date:  2015-03-10       Impact factor: 2.836

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.